Study of how interstitial lung disease naturally changes
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This study looks at how interstitial lung disease (lung scarring) typically progresses over time. It may help researchers understand what to expect and what changes to watch for.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have interstitial lung disease (lung scarring).
- You must be able to participate as someone currently diagnosed with ILD.
- You should not be enrolled if you do not have ILD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
This study is looking at people with Idiopathic Pulmonary Fibrosis (IPF), a type of lung scarring. Researchers will use medical records to see if they can better predict how the disease will progress over time.
This study looks at what factors contribute to worsening lung scarring seen on scans in people with certain lung diseases. Results may help doctors better understand and predict who will worsen over time.
This study follows people with systemic sclerosis who also have lung scarring (interstitial lung disease). It aims to map how lung function and lung images change over time, which may help doctors predict and better manage disease progression.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.